We are live on
!
Find out more
Lineage Cell Therapeutics
LCTX
LCTX
89 hedge funds and large institutions have $96.9M invested in Lineage Cell Therapeutics in 2020 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 19 increasing their positions, 15 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
1,983% more call options, than puts
Call options by funds: $1.44M | Put options by funds: $69K
130% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 10
95% more capital invested
Capital invested by funds: $49.8M → $96.9M (+$47.1M)
27% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 15
17% more funds holding
Funds holding: 76 → 89 (+13)
0.98% more ownership
Funds ownership: 35.73% → 36.72% (+0.98%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Holders
89
Holders Change
+13
Holders Change %
+17.11%
% of All Funds
1.57%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
23
Increased
19
Reduced
15
Closed
10
Calls
$1.44M
Puts
$69K
Net Calls
+$1.37M
Net Calls Change
+$1.3M
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.37M |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
+$1.11M |
| 3 |
Two Sigma Investments
New York
|
+$472K |
| 4 |
Two Sigma Advisers
New York
|
+$241K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$191K |
